New calcium pill could ease burden for hypoparathyroidism patients
NCT ID NCT06547151
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a new form of calcium called AMOR-1 in 81 adults with hypoparathyroidism, a condition where the body can't control calcium levels. Participants will take either AMOR-1 or standard calcium pills to see if AMOR-1 can better maintain normal calcium levels while allowing them to take less calcium overall. The trial is double-blind, meaning neither patients nor doctors know who gets which treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Amorphous Calcium Carbonate (AMOR-1)
What this could lead to
If successful, this could offer a more effective way to manage calcium levels in people with hypoparathyroidism, potentially reducing the need for high-dose calcium supplements.
What could go wrong
This is an early Phase 2 trial with only 81 participants, so results may not apply to everyone. The treatment may not work better than standard calcium, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Assuta Ashdod medical center
RECRUITINGAshdod, Israel, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Barzilai Medical Center
ACTIVE_NOT_RECRUITINGAshkelon, Israel
-
Hadassah Ein Kerem Medical Center
RECRUITINGJerusalem, Israel, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kaplan Medical Center
NOT_YET_RECRUITINGRehovot, Israel
Contact Email: •••••@•••••
Contact
Contact
Contact
Contact
-
Rabin Medical Center, Belinson Campus
RECRUITINGPetah Tikva, Israel, 49100, Israel
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rambam Medical Center
NOT_YET_RECRUITINGHaifa, Israel
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sheba Medical Center
RECRUITINGRamat Gan, Israel
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Soroka Medical Center
RECRUITINGBeersheba, Israel
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact